IL5 and chronic obstructive pulmonary disease: Thus, if eosinophilic inflammation may represent a new therapeutic target in COPD, blocking the IL-5 signaling pathway by directly binding the alpha chain of the cytokine (e.g., mepolizumab, reslizumab) or inhibiting its receptor (e.g., benralizumab) may represent one the most effective strategies [48].